| Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease K Magyar, R Halmosi, A Palfi, G Feher, L Czopf, A Fulop, I Battyany, ... Clinical hemorheology and microcirculation 50 (3), 179-187, 2012 | 413 | 2012 |
| Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat E Szabados, GM Fischer, K Toth, B Csete, B Nemeti, K Trombitas, ... Free Radical Biology and Medicine 26 (3-4), 309-317, 1999 | 173 | 1999 |
| BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly (ADP-ribose) polymerase E Szabados, P Literati-Nagy, B Farkas, B Sumegi Biochemical pharmacology 59 (8), 937-945, 2000 | 118 | 2000 |
| Cardioprotective effect of resveratrol in a postinfarction heart failure model A Riba, L Deres, B Sumegi, K Toth, E Szabados, R Halmosi Oxidative medicine and cellular longevity 2017 (1), 6819281, 2017 | 108 | 2017 |
| The effects of SGLT2 inhibitors on lipid metabolism Z Szekeres, K Toth, E Szabados Metabolites 11 (2), 87, 2021 | 107 | 2021 |
| PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats E Bartha, I Solti, L Kereskai, J Lantos, E Plozer, K Magyar, E Szabados, ... Cardiovascular research 83 (3), 501-510, 2009 | 84 | 2009 |
| PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3β pathway A Palfi, A Toth, K Hanto, P Deres, E Szabados, Z Szereday, G Kulcsar, ... Journal of molecular and cellular cardiology 41 (1), 149-159, 2006 | 80 | 2006 |
| Enhanced ADP-ribosylation and its diminution by lipoamide after ischemia-reperfusion in perfused rat heart E Szabados, GM Fischer, F Gallyas Jr, G Kispal, B Sumegi Free radical biology and medicine 27 (9-10), 1103-1113, 1999 | 60 | 1999 |
| The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly (ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol … A Pálfi, A Tóth, G Kulcsár, K Hantó, P Deres, E Bartha, R Halmosi, ... Journal of Pharmacology and Experimental Therapeutics 315 (1), 273-282, 2005 | 58 | 2005 |
| The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals T Habon, E Szabados, G Kesmarky, R Halmosi, T Past, B Sumegi, K Toth Cardiovascular research 52 (1), 153-160, 2001 | 58 | 2001 |
| Effects of moderate aerobic exercise training on hemorheological and laboratory parameters in ischemic heart disease patients B Sandor, A Nagy, A Toth, M Rabai, B Mezey, A Csatho, I Czuriga, K Toth, ... PloS one 9 (10), e110751, 2014 | 57 | 2014 |
| Doxycycline protects against ROS-induced mitochondrial fragmentation and ISO-induced heart failure A Riba, L Deres, K Eros, A Szabo, K Magyar, B Sumegi, K Toth, ... PLoS One 12 (4), e0175195, 2017 | 52 | 2017 |
| Regulation of kinase cascade activation and heat shock protein expression by poly (ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure E Bartha, I Solti, A Szabo, G Olah, K Magyar, E Szabados, T Kalai, ... Journal of cardiovascular pharmacology 58 (4), 380-391, 2011 | 32 | 2011 |
| Use of octreotide in the treatment of chylopericardium E Szabados, K Toth, E Mezosi heart & lung 40 (6), 574-575, 2011 | 29 | 2011 |
| Association between obesity and overweight and cardiorespiratory and muscle performance in adolescents P Petrovics, B Sandor, A Palfi, Z Szekeres, T Atlasz, K Toth, E Szabados International journal of environmental research and public health 18 (1), 134, 2021 | 27 | 2021 |
| Cardiac arrest in Kearns–Sayre syndrome I van Beynum, E Morava, M Taher, RJ Rodenburg, J Karteszi, K Toth, ... JIMD Reports-Case and Research Reports, 2011/2, 7-10, 2012 | 26 | 2012 |
| Association of exercise capacity with physical functionality and various aspects of fatigue in patients with coronary artery disease A Nagy, E Szabados, A Simon, B Mezey, B Sándor, I Tiringer, K Tóth, ... Behavioral Medicine 44 (1), 28-35, 2018 | 14 | 2018 |
| Cardiovascularis prevenció–2016 A Vértes, E Szabados Orvosi Hetilap 157 (38), 1526-1531, 2016 | 11 | 2016 |
| Clinical study of metabolic parameters, leptin and the SGLT2 inhibitor empagliflozin among patients with obesity and type 2 diabetes Z Szekeres, B Sandor, Z Bognar, FHJ Ramadan, A Palfi, B Bodis, K Toth, ... International Journal of Molecular Sciences 24 (5), 4405, 2023 | 10 | 2023 |
| A kardiológiai rehabilitáció teljesítménymutatói Magyarországon. I Boncz, A Sebestyén, T Csákvári, I Ágoston, E Szabados, D Endrei Hungarian Medical Journal/Orvosi Hetilap 160, 2019 | 10 | 2019 |
